Author:
Dejnirattisai Wanwisa,Shaw Robert H,Supasa Piyada,Liu Chang,Stuart Arabella SV,Pollard Andrew J,Liu Xinxue,Lambe Teresa,Crook Derrick,Stuart Dave I,Mongkolsapaya Juthathip,Nguyen-Van-Tam Jonathan S,Snape Matthew D,Screaton Gavin R,
Abstract
AbstractIn this report, we present live neutralisation titres against SARS-CoV-2 Omicron variant, compared with neutralisation against Victoria, Beta and Delta variants. Sera from day-28 post second-dose were obtained from participants in the Com-COV2 study who had received a two-dose COVID-19 vaccination schedule with either AstraZeneca (AZD1222) or Pfizer (BNT162b2) vaccines. There was a substantial fall in neutralisation titres in recipients of both AZD1222 and BNT16b2 primary courses, with evidence of some recipients failing to neutralise at all. This will likely lead to increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection, although there is currently no evidence of increased potential to cause severe disease, hospitalization or death.
Publisher
Cold Spring Harbor Laboratory
Reference6 articles.
1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int (accessed Dec 08, 2021).
2. Zahradník J , Tuekprakhon A , Ginn HM , et al. Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution. bioRxiv. 2021; (published online Dec 07.) (preprint) [https://doi.org/10.1101/2021.12.03.471045M
3. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (accessed Dec 08, 2021)
4. Stuart ASV , Shaw RH , Liu X , et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase2, non-inferiority trial. Lancet 2021; (published online Dec 06) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02718-5/fulltext#%20
5. Cele, S , Jackson L , Khan, K et al. SARRC-Cov_2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralisation and requires ACE2 for infection. 2021 (published online Dec) https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献